- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Lipitor may be the first statin to switch to OTC
- Teva launches authorized generic version of Pfizer's Detrol LA
- WSJ: Pfizer recruiting for Lipitor OTC actual use study
- Federal government must find alternatives to rescheduling hydrocodone combination drugs
PEAPACK, N.J. — Greenstone has launched a version of a drug used to treat fungal infections, the company said.
Greenstone, the generics subsidiary of Pfizer, announced the introduction of voriconazole for oral suspension, an authorized generic version of Pfizer's Vfend. Authorized generics are branded drugs sold at a discount under their generic names.
Greenstone is selling the drug in the 40 mg-per-milliliter strength. Vfend had sales of about $17.1 million during the 12-month period that ended in June, according to IMS Health.